BOK Financial Private Wealth Inc. Lowers Holdings in Abbott Laboratories (NYSE:ABT)

BOK Financial Private Wealth Inc. reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 14.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,155 shares of the healthcare product maker’s stock after selling 2,155 shares during the quarter. BOK Financial Private Wealth Inc.’s holdings in Abbott Laboratories were worth $1,488,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Miramar Capital LLC raised its position in shares of Abbott Laboratories by 0.4% during the fourth quarter. Miramar Capital LLC now owns 79,033 shares of the healthcare product maker’s stock valued at $8,939,000 after buying an additional 280 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $1,332,000. Naviter Wealth LLC raised its position in shares of Abbott Laboratories by 14.2% during the fourth quarter. Naviter Wealth LLC now owns 24,876 shares of the healthcare product maker’s stock valued at $2,814,000 after buying an additional 3,090 shares during the last quarter. Rialto Wealth Management LLC bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $29,000. Finally, Larson Financial Group LLC raised its position in shares of Abbott Laboratories by 32.4% during the fourth quarter. Larson Financial Group LLC now owns 16,349 shares of the healthcare product maker’s stock valued at $1,849,000 after buying an additional 4,005 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 1.6 %

Shares of ABT opened at $137.23 on Friday. The firm has a market capitalization of $238.00 billion, a P/E ratio of 17.94, a P/E/G ratio of 2.52 and a beta of 0.70. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The firm has a fifty day moving average price of $125.35 and a 200-day moving average price of $118.76.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.34. The firm had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business’s revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.19 earnings per share. Equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a $0.59 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.72%. Abbott Laboratories’s payout ratio is presently 30.85%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ABT shares. Wells Fargo & Company boosted their price target on shares of Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, January 23rd. Barclays restated an “overweight” rating and issued a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a research report on Monday, January 27th. Royal Bank of Canada restated an “outperform” rating and issued a $135.00 price target on shares of Abbott Laboratories in a research report on Tuesday, January 21st. Evercore ISI boosted their price target on shares of Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a research report on Thursday, January 2nd. Finally, Citigroup boosted their price target on shares of Abbott Laboratories from $135.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $137.19.

Insider Activity

In other Abbott Laboratories news, SVP Eric Shroff sold 562 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $77,651.54. Following the sale, the senior vice president now owns 31,970 shares of the company’s stock, valued at approximately $4,417,294.90. This trade represents a 1.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the business’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total value of $12,199,967.94. Following the completion of the transaction, the executive vice president now directly owns 71,928 shares of the company’s stock, valued at approximately $9,625,404.96. The trade was a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 116,449 shares of company stock worth $15,463,316. Corporate insiders own 1.10% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.